Company Description
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas.
Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
The company’s lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials.
It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer’s Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors.
The company was founded in 2017 and is headquartered in Bethesda, Maryland.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Gene Mack |
Contact Details
Address: 4800 Montgomery Lane, Suite 220 Bethesda, Maryland 20814 United States | |
| Phone | 301 500 1556 |
| Website | gaintherapeutics.com |
Stock Details
| Ticker Symbol | GANX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001819411 |
| CUSIP Number | 36269B105 |
| ISIN Number | US36269B1052 |
| Employer ID | 85-1726310 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gene Mack M.B.A. | President, Chief Executive Officer and Director |
| Dr. Khalid Islam Ph.D. | Executive Chairman |
| Gianluca Fuggetta | Senior Vice President of Finance and Principal Financial Officer |
| Dr. Joanne Taylor Ph.D. | Senior Vice President of Research |
| Dr. Terenzio Ignoni Pharm.D. | Senior Vice President of Technical Operations |
| Dr. Jonas Hannestad M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 10, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Feb 6, 2025 | 8-K | Current Report |
| Jan 15, 2025 | 8-K | Current Report |
| Jan 7, 2025 | 8-K | Current Report |
| Dec 23, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |